We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AdvaMed Shifting Focus From FDA to CMS, Still Pushing for Tax Repeal
AdvaMed Shifting Focus From FDA to CMS, Still Pushing for Tax Repeal
FDA’s continued progress under MDUFA is allowing AdvaMed to shift some of its focus from the pace of premarket reviews and approvals to the Center for Medicare & Medicaid Services’ methods for making coverage decisions on new technologies, association officials said Tuesday.